With one quarter of ownership and a one time ₹50L capex, every rupee must compound past Day 90. Recommendation: go retention heavy (85%) via software and playbooks that keep paying forever, and run a lean clinic pilot (15%) with setup cost only, no lease commitments.
85% of ₹50L · ₹42.5L
15% of ₹50L · ₹7.5L setup only
+8 pp inside the quarter
Near full payback in 90 days
Acquisition is healthy. The P&L damage happens at the very first refill, an activation problem masquerading as a retention problem.
| Stage | Users | Conversion |
|---|---|---|
| O1 start | 100 | |
| O2 retained | 34 | |
| O3 retained | 19 |
35% of O1 users receive zero coach calls in the first 21 days. Coach cost (₹120/user/mo) is already paid, so this is unused inventory, not a budget problem.
Male O1 to O2 36% vs. Female 31%. Likely rooted in protocol design, content tone and side effect anxiety. A dedicated female track is high leverage.
Only 17% DAU among O1. Users who open the app daily in weeks 1 to 3 retain materially better across subscription businesses, so this is an activation moat we're leaving unlocked.
With a non recurring ₹50L and 90 days of ownership, a full format clinic (₹9.7L/month recurring) is a commitment I cannot fund. Retention tech, by contrast, keeps paying long after the quarter ends. Split is 85/15.
Reallocate existing coach minutes using AI assisted triage. Move the 35% "0 call" cohort to ≥1 structured call. Script focuses on side effect reassurance & expectation setting.
Target: O1 to O2 +5pp · Cost: ₹8L
Dedicated female derm consult slot, reformulated messaging, PCOS / postpartum lens. Content library refresh.
Target: Close 5pp gender gap · Cost: ₹10L
Weekly progress photo ritual, streaks, refill countdown. Push DAU 17% to 30% on O1.
Target: O1 to O2 +2pp · Cost: ₹12L
Opt out subscription at O1 checkout with a "pause anytime" guarantee. Addresses passive churn.
Target: O1 to O2 +1pp · Cost: ₹5L
| O1 starts | 1,100 × 37% = 407 |
| Month 1 revenue | 407 × ₹3,300 = ₹13.4L |
| Gross profit @ 62% | ₹8.3L |
| Fixed costs | minus ₹9.7L |
| Halo lift (14% on ~1,800 local digital leads) | + ₹4.5L |
| Net contribution | + ₹3.1L |
Clinic acquired O1 to O2 not in brief. Assumption: derm consult + ₹3,300 AOV signals higher intent vs. digital.
| Scenario | Clinic O1 to O2 | Verdict |
|---|---|---|
| Worst | 30% | kill |
| Base | 42% | pilot |
| Best | 48% | scale Q2 |
Base case is the working assumption for this deck. Quarter 1 proves or kills it.
| Initiative | Spend | Type |
|---|---|---|
| Coach playbook + AI triage | ₹8L | Tooling |
| Female protocol track | ₹10L | Content |
| App activation engine | ₹15L | Eng + CRM |
| Auto refill at checkout | ₹5L | Eng |
| 1 Mumbai clinic pilot (setup) | ₹7.5L | Capex only |
| Experimentation + measurement | ₹4.5L | A/B infra |
| Total | ₹50L |
| Lever | Δ O1 to O2 | Δ GP |
|---|---|---|
| Coach playbook | +5 pp | ₹22.5L |
| Female track | +1.5 pp | ₹6.7L |
| App activation | +2 pp | ₹9.0L |
| Auto refill | +1 pp | ₹4.5L |
| Mumbai pilot halo | ₹3.0L | |
| Total | +9.5 pp | ~₹45.7L |
In quarter payback: 91%. Beyond Q1, tech assets keep compounding at zero marginal cost — that's the win.
Key assumptions: O1 to O2 stable at 34% (per brief) · AOV ₹2,900 · GM 62% · clinic acquired retention assumed at 42% base case · no coach headcount added · halo measured via geo holdout.